SecBot SecBot
8-K ·Filed Aug 5, 2026

COR

Cencora, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001140859-26-000032
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The beat-and-raise quarter with accelerated buybacks is a clear positive. Monitor the Q4 print for continued execution on OneOncology integration and margin expansion in U.S. Healthcare Solutions. The accelerated $1B buyback signals management confidence in cash flow generation.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$317.22
T+0 close · Aug 5, 2026 · via day close
Latest settled
+3.48%
T+60 · $328.25
Vs SPY
+3.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $317.22entry
  2. T+1 · 3mo ago +2.46%α +2.62% · $325.01
  3. T+5 · 3mo ago −0.96%α −1.31% · $314.17
  4. T+20 · 3mo ago +6.03%α +6.64% · $336.36
  5. T+60 · 18d ago +3.48%α +3.28% · $328.25
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cencora reported fiscal Q3 2026 revenue of $84.8B (+5.1% YoY) and adjusted diluted EPS of $4.48, beating consensus estimates of $4.35 by 3.0%. The company raised its full-year adjusted EPS guidance to $17.75-$17.95 and repurchased $1B in shares during the quarter, signaling strong operational momentum and capital return to shareholders.

Key Financial Metrics

EPS
$4.48
est $4.35 · +3.0%
Revenue
$84.8B
est $84.2B · +0.7% · +5.1% YoY
Rating
beat
Guidance
4% to 6% growth
raised
Free Cash Flow
$1.2B
Gross Margin
4.26%

Key Facts

  • Revenue of $84.8B, up 5.1% YoY, beating $84.15B consensus
  • Adjusted diluted EPS of $4.48, up 12.0% YoY, beating $4.35 consensus
  • FY2026 adjusted EPS guidance raised to $17.75-$17.95 from $17.70-$17.90
  • Repurchased $1B in shares during Q3, accelerating the prior $1B target from end of calendar 2026
  • U.S. Healthcare Solutions segment operating income up 15.9% YoY, driven by OneOncology acquisition
  • International Healthcare Solutions segment operating income up 20.8% YoY
  • GAAP diluted EPS of $3.94, up 11.9% YoY
  • Quarterly dividend maintained at $0.60 per share

Financial Impact

Revenue beat consensus by ~$650M; adjusted EPS beat by $0.13 (3.0%); FY guidance raised by $0.05 at midpoint

revenueepsguidanceshare repurchases

Risk Factors

  • Higher interest expense ($140.7M, +72% YoY) from debt financing of OneOncology
  • GLP-1 mix shift continues to pressure gross margins
  • Opioid litigation liability remains at $3.8B on balance sheet

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Analyst Consensus
75% bullish (20 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140859-26-000032
Document: abc-20260805.htm0001140859-26-000032
Document: 0001140859-26-000032-index-headers.html0001140859-26-000032
Document: 0001140859-26-000032-index.html0001140859-26-000032
Document: 0001140859-26-000032.txt0001140859-26-000032
8-K Data (Synthetic)0001140859-26-000032

Track record

12 reports on COR

Performance horizon

0 of 3 bullish or bearish reports moved the stock their way by T+1. Best: −0.32% at T+1 after the Feb 28, 2026 report. 0 of 3 went positive at some point.

Filters
  1. Nov 4, 202612d ago 8-K Neutral 2/10 Entry $354.00 to $339.68 Now $357.68 +1.04% ▼ −4.05% +0.36% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $354.00 to $339.68 Now $357.68 +1.04% ▼ −4.05% +0.36% vs SPY
  3. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $340.43 to $338.48 Now $357.68 +5.07% ▼ −0.57% +0.61% vs SPY
  4. Oct 20, 202627d ago Institutional Cluster Mixed 3/10 Entry $340.43 to $338.48 Now $357.68 +5.07% ▼ −0.57% +0.61% vs SPY
  5. Sep 25, 20267w ago 8-K Neutral 2/10 Entry $306.92 to $303.81 Now $357.68 +16.54% ▼ −1.01% −0.27% vs SPY
  6. Aug 21, 202612w ago Institutional Cluster Mixed 6/10 Entry $318.04 to $323.77 Now $357.68 +12.46% ▲ +1.80% +2.10% vs SPY
  7. Aug 5, 202614w ago 8-K Neutral 3/10 Entry $317.22 to $325.01 Now $357.68 +12.75% ▲ +2.46% +2.62% vs SPY
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Viewing Entry $317.22 to $325.01 Now $357.68 +12.75% ▲ +2.46% +2.62% vs SPY
  9. Jun 15, 202621w ago 8-K Neutral 2/10 Entry $281.46 to $277.09 Now $357.68 +27.08% ▼ −1.55% −0.30% vs SPY
  10. May 29, 202624w ago 8-K Neutral 3/10 Entry $264.69 to $264.84 Now $357.68 +35.13% ▲ +0.06% −0.10% vs SPY
Showing 10 of 12

US Market Status

Market Open · Closes in 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026